AstraZeneca Veteran Dr. Alan Barge Appointed CEO of 4C Biomed to Accelerate Immuno-Oncology Pipeline
AstraZeneca Oncology Veteran Dr. Alan Barge Named CEO of 4C Biomed
London, UK — In a major strategic move to accelerate its transition into a clinical-stage biotech firm, 4C Biomed has announced the appointment of Dr. Alan Barge, MD, as its new Chief Executive Officer. Dr. Barge, a highly distinguished biopharmaceutical executive with over 35 years of oncology drug development experience, assumed the role with immediate effect.
He succeeds Eyal Greenberg, who will transition to the roles of Chief Development Officer and General Manager of Research and Development (R&D).
Driving the Transition to Clinical Trials
The leadership transition comes at a pivotal moment for 4C Biomed, a London-headquartered immuno-oncology firm with research operations in Israel. The executive restructuring is explicitly designed to advance the company's lead pipeline programs into human trials.
Key objectives under Dr. Barge’s new leadership include:
- Accelerating Phase I Entry: Preparing the company's lead therapeutic candidates for planned Phase I clinical trials in Q1 2027.
- Targeting High-Expression Solid Tumors: Advancing the company's proprietary anti-HVEM (herpesvirus entry mediator) blockade program, anti-4CB1.
- Expanding Pre-Clinical Validation: Building upon pre-clinical research that demonstrates the therapeutic efficacy of anti-HVEM blockade across multiple highly aggressive solid cancers.
The lead candidate, anti-4CB1, is being actively developed to target several solid tumor types where HVEM is highly expressed, including:
- Melanoma
- Renal cell carcinoma
- Ovarian cancer
- Colorectal and endometrial cancers
- Hepatocellular carcinoma
A Proven Legacy in Oncology Innovation
Dr. Alan Barge brings a wealth of high-profile industry experience to 4C Biomed. Notably, during a stellar 14-year career at AstraZeneca, he rose to serve as Vice President and Head of Oncology and Infection. During his tenure, he was instrumental in overseeing the clinical development of blockbuster cancer therapies, including:
- Lynparza (olaparib): The first approved PARP inhibitor, which revolutionized targeted therapy for BRCA-mutated cancers.
- Iressa (gefitinib): A pioneer in personalized medicine and targeted therapies for non-small cell lung cancer (NSCLC).
Beyond his tenure at AstraZeneca, Dr. Barge has a proven track record of building and scaling oncology startups. He has served as the co-founder of both Carrick Therapeutics and ASLAN Pharmaceuticals, and has held executive roles at Amgen and Tilikum Therapeutics.
Strategic Vision for 4C Biomed
4C Biomed's unique focus on overcoming resistance to first-generation checkpoint inhibitors positions it at the cutting edge of oncology. Under Dr. Barge's stewardship, the company will focus on securing translational data and building international partnerships to bring its novel immunotherapies to market.
With a clear roadmap leading to clinical trials in early 2027, the appointment of Dr. Barge signals a bold and highly focused chapter for the biotech innovator.